Another study from Taiwan showed that the use of SGLT2 inhibitors when compared to that of DPP4 inhibitors was associated with a 39% reduction (95% CI, 27%–50%) in the risk of new-onset AF (Ling et al., 2020). The gene discussed is SLC5A2; the disease is atrial fibrillation.